Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay.
Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay.
复制标题
DOI：
10.1158/0008-5472.can-13-0813
复制
发表时间：
2014-04-15
期刊：
影响因子：
11.2
通讯作者：
Dorsey JF
中科院分区：
文献类型：
--
作者：
Macarthur KM;Kao GD;Chandrasekaran S;Alonso-Basanta M;Chapman C;Lustig RA;Wileyto EP;Hahn SM;Dorsey JF
检测循环肿瘤细胞（CTC）的血液检测为监测疾病状态、评估预后和指导癌症患者的治疗决策提供了巨大的潜力。对于患有脑肿瘤的患者，例如侵袭性多形性胶质母细胞瘤，需要CTC测定，其不依赖于脑肿瘤往往缺乏的癌细胞表面生物标志物如上皮细胞粘附分子的表达。在这里，我们描述了一种基于端粒酶活性检测CTC的策略，端粒酶活性在几乎所有肿瘤细胞中升高，但在正常细胞中不升高。该策略使用腺病毒检测系统，该系统被证明可以成功检测脑肿瘤患者的CTC。临床数据表明，该测定可能有助于解释接受放射治疗的患者的治疗反应，例如，区分假进展与真正的肿瘤进展。这些结果支持进一步开发该测定法作为检测癌症患者中CTC的通用方法。
Blood tests to detect circulating tumor cells (CTC) offer great potential to monitor disease status, gauge prognosis, and guide treatment decisions for patients with cancer. For patients with brain tumors, such as aggressive glioblastoma multiforme, CTC assays are needed that do not rely on expression of cancer cell surface biomarkers like epithelial cell adhesion molecules that brain tumors tend to lack. Here, we describe a strategy to detect CTC based on telomerase activity, which is elevated in nearly all tumor cells but not normal cells. This strategy uses an adenoviral detection system that is shown to successfully detect CTC in patients with brain tumors. Clinical data suggest that this assay might assist interpretation of treatment response in patients receiving radiotherapy, for example, to differentiate pseudoprogression from true tumor progression. These results support further development of this assay as a generalized method to detect CTC in patients with cancer.